Viatris Buys Two Eye Specialists, Setting The Stage For ‘Phase Two’ Of Its Growth Plan
Acquisitions Could Add $1bn To Net Sales By 2028
The company will buy Oyster Point Pharma and Famy Life Sciences for $700m to $750m in total as management tries to move the business towards more innovation.
